Zacks Research Issues Negative Estimate for Amarin Earnings

Key Points

• Zacks Research has significantly revised Amarin's Q3 2025 earnings per share estimate from $0.45 to ($0.02), indicating a notable decline in projected earnings.
• The company's recent quarterly earnings showed a loss of ($0.03) EPS, surpassing estimates but still reflecting ongoing financial challenges with a negative return on equity of 21.18%.
• Various analysts have issued contrasting ratings for Amarin, with one upgrade to "buy" and others maintaining or issuing a "sell" rating, suggesting mixed sentiments about the stock’s future performance.

Amarin Corporation PLC (NASDAQ:AMRN - Free Report) - Equities research analysts at Zacks Research cut their Q3 2025 earnings per share (EPS) estimates for Amarin in a research note issued on Monday, October 6th. Zacks Research analyst Team now expects that the biopharmaceutical company will earn ($0.02) per share for the quarter, down from their previous estimate of $0.45. Zacks Research has a "Hold" rating on the stock. The consensus estimate for Amarin's current full-year earnings is ($0.15) per share. Zacks Research also issued estimates for Amarin's Q4 2025 earnings at ($0.22) EPS, Q3 2026 earnings at ($0.38) EPS, Q4 2026 earnings at ($0.61) EPS, FY2026 earnings at ($0.07) EPS, Q1 2027 earnings at $0.21 EPS, Q2 2027 earnings at $0.34 EPS, Q3 2027 earnings at ($0.04) EPS and FY2027 earnings at $0.14 EPS.

Amarin (NASDAQ:AMRN - Get Free Report) last posted its quarterly earnings data on Wednesday, July 30th. The biopharmaceutical company reported ($0.03) EPS for the quarter, beating the consensus estimate of ($0.66) by $0.63. Amarin had a negative return on equity of 21.18% and a negative net margin of 47.22%.The business had revenue of $72.74 million for the quarter, compared to the consensus estimate of $45.45 million.

Other equities analysts also recently issued research reports about the company. The Goldman Sachs Group upped their price objective on Amarin from $7.00 to $12.00 and gave the company a "sell" rating in a research note on Wednesday, June 25th. Wall Street Zen upgraded Amarin from a "hold" rating to a "buy" rating in a research note on Saturday, August 2nd. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Amarin in a research note on Wednesday. One equities research analyst has rated the stock with a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Sell" and an average target price of $12.00.

Amarin Trading Up 0.1%

Amarin stock opened at $19.28 on Thursday. Amarin has a 12 month low of $7.08 and a 12 month high of $20.43. The business's 50 day simple moving average is $15.66 and its 200 day simple moving average is $13.37. The company has a market cap of $398.71 million, a price-to-earnings ratio of -5.25 and a beta of 0.62.

Institutional Investors Weigh In On Amarin

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. GPS Wealth Strategies Group LLC bought a new stake in Amarin during the 2nd quarter valued at $32,000. Headlands Technologies LLC bought a new stake in Amarin during the second quarter valued at $44,000. Kornitzer Capital Management Inc. KS grew its position in Amarin by 4.0% during the first quarter. Kornitzer Capital Management Inc. KS now owns 88,200 shares of the biopharmaceutical company's stock worth $40,000 after buying an additional 3,400 shares in the last quarter. LCM Capital Management Inc grew its position in Amarin by 2.4% during the first quarter. LCM Capital Management Inc now owns 858,259 shares of the biopharmaceutical company's stock worth $385,000 after buying an additional 20,000 shares in the last quarter. Finally, Waterfront Wealth Inc. grew its position in Amarin by 1.3% during the first quarter. Waterfront Wealth Inc. now owns 2,514,615 shares of the biopharmaceutical company's stock worth $1,127,000 after buying an additional 32,849 shares in the last quarter. Institutional investors own 22.25% of the company's stock.

About Amarin

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.